Insider Selling: ResMed Inc. (RMD) Insider Sells 2,810 Shares of Stock

ResMed Inc. (NYSE:RMD) insider David Pendarvis sold 2,810 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $96.03, for a total transaction of $269,844.30. Following the completion of the sale, the insider now owns 97,263 shares of the company’s stock, valued at $9,340,165.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

David Pendarvis also recently made the following trade(s):

  • On Monday, December 4th, David Pendarvis sold 2,804 shares of ResMed stock. The shares were sold at an average price of $84.17, for a total transaction of $236,012.68.

ResMed Inc. (NYSE RMD) traded up $1.72 during trading hours on Tuesday, hitting $95.05. 1,203,730 shares of the stock traded hands, compared to its average volume of 902,297. ResMed Inc. has a 1-year low of $67.04 and a 1-year high of $104.78. The firm has a market capitalization of $13,490.00, a P/E ratio of 47.76 and a beta of 0.92.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Monday, January 22nd. The medical equipment provider reported $1.00 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.22. ResMed had a net margin of 12.98% and a return on equity of 22.75%. The business had revenue of $601.27 million during the quarter, compared to the consensus estimate of $583.77 million. During the same period in the previous year, the firm posted $0.73 earnings per share. The business’s revenue for the quarter was up 13.4% compared to the same quarter last year. analysts expect that ResMed Inc. will post 3.34 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Thursday, February 8th will be issued a dividend of $0.35 per share. The ex-dividend date of this dividend is Wednesday, February 7th. This represents a $1.40 annualized dividend and a dividend yield of 1.47%. ResMed’s dividend payout ratio (DPR) is presently 70.35%.

Several institutional investors have recently modified their holdings of the stock. Crossmark Global Holdings Inc. raised its holdings in shares of ResMed by 9.0% during the fourth quarter. Crossmark Global Holdings Inc. now owns 107,882 shares of the medical equipment provider’s stock worth $9,137,000 after purchasing an additional 8,939 shares during the last quarter. Stephens Investment Management Group LLC raised its holdings in shares of ResMed by 0.3% during the fourth quarter. Stephens Investment Management Group LLC now owns 357,782 shares of the medical equipment provider’s stock worth $30,301,000 after purchasing an additional 1,068 shares during the last quarter. Calton & Associates Inc. purchased a new position in shares of ResMed during the fourth quarter worth $115,000. Dowling & Yahnke LLC purchased a new position in shares of ResMed during the fourth quarter worth $208,000. Finally, Public Employees Retirement Association of Colorado raised its holdings in shares of ResMed by 3.4% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 27,251 shares of the medical equipment provider’s stock worth $2,308,000 after purchasing an additional 889 shares during the last quarter. 61.41% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently commented on RMD shares. BMO Capital Markets lifted their price objective on shares of ResMed from $70.00 to $74.00 and gave the stock a “market perform” rating in a research note on Friday, October 27th. Needham & Company LLC reiterated a “sell” rating on shares of ResMed in a research note on Friday, October 27th. Zacks Investment Research downgraded shares of ResMed from a “buy” rating to a “sell” rating in a research note on Tuesday, October 24th. JPMorgan Chase & Co. lifted their price objective on shares of ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a research note on Monday, October 30th. Finally, Barclays lifted their price objective on shares of ResMed from $68.00 to $70.00 and gave the stock an “underweight” rating in a research note on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. ResMed currently has an average rating of “Hold” and an average target price of $73.57.

COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/06/insider-selling-resmed-inc-rmd-insider-sells-2810-shares-of-stock.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply